- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Podcast
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
Author(s):
This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, the IL-17 drug class, how bimekizumab is different, plus more.
This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, as well as discusses the interleukin(IL)-17 class of biologics, how this class compares to other classes such as IL-23 and TNFα, and how bimekizumab (UCB) sets itself apart from other biologics in the pipeline for psoriasis.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Larry Eichenfield, MD: Icotrokinra Demonstrates Promising Results for Adolescents With Moderate to Severe Plaque Psoriasis
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis
Clinical Attributes of IL-17 Inhibitors in Psoriasis
Mechanism of Action Differences Among IL-17 Inhibitors
The Role of IL-17 in Psoriasis Pathogenesis
New Research Confirms Effective Therapy for Nail Psoriasis
Related Content
